These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11212273)

  • 1. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice.
    Nilsson F; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2001 Jan; 61(2):711-6. PubMed ID: 11212273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.
    Halin C; Rondini S; Nilsson F; Berndt A; Kosmehl H; Zardi L; Neri D
    Nat Biotechnol; 2002 Mar; 20(3):264-9. PubMed ID: 11875427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.
    Kaspar M; Trachsel E; Neri D
    Cancer Res; 2007 May; 67(10):4940-8. PubMed ID: 17510424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
    Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
    Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors.
    Birchler MT; Milisavlijevic D; Pfaltz M; Neri D; Odermatt B; Schmid S; Stoeckli SJ
    Laryngoscope; 2003 Jul; 113(7):1231-7. PubMed ID: 12838025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
    Frey K; Zivanovic A; Schwager K; Neri D
    Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
    Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
    Harada H; Hiraoka M; Kizaka-Kondoh S
    Cancer Res; 2002 Apr; 62(7):2013-8. PubMed ID: 11929818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
    Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
    Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment.
    El-Sheikh A; Borgstrom P; Bhattacharjee G; Belting M; Edgington TS
    Cancer Res; 2005 Dec; 65(23):11109-17. PubMed ID: 16322261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
    Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
    Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment.
    Birchler M; Viti F; Zardi L; Spiess B; Neri D
    Nat Biotechnol; 1999 Oct; 17(10):984-8. PubMed ID: 10504699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.
    Balza E; Mortara L; Sassi F; Monteghirfo S; Carnemolla B; Castellani P; Neri D; Accolla RS; Zardi L; Borsi L
    Clin Cancer Res; 2006 Apr; 12(8):2575-82. PubMed ID: 16638868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
    Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
    Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
    Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.
    Cooke SP; Boxer GM; Lawrence L; Pedley RB; Spencer DI; Begent RH; Chester KA
    Cancer Res; 2001 May; 61(9):3653-9. PubMed ID: 11325835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.